{
  "id": 9321587,
  "title": "Guggenheim upgrades Editas Medicine stock rating on gene editing therapy",
  "url": "https://urgent.news/2026/09/23/guggenheim-upgrades-editas-medicine-stock-rating-on-gene-editing",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-23T11:12:45.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/guggenheim-upgrades-editas-medicine-stock-rating-on-gene-editing-therapy-93CH-4912716"
  },
  "original_language": "en",
  "account": "Guggenheim upgraded Editas Medicine's stock rating to Buy and set a price target of $5.00 per share on Monday, following a 7.75% increase in the stock price to $2.92 over the past week. This came with a notable 42% gain in value over the year-to-date period. The firm's updated model focuses on EDIT-401, a gene editing therapy aimed at treating severe hypercholesterolemia. Preclinical trials demonstrated the treatment's effectiveness in reducing LDL-C levels by over 90% and ApoB levels by more than 70% at a therapeutic dosage. EDIT-401 works by upregulating LDLR expression through the generation of a large deletion or inversion in the gene's 3' untranslated region using dual gRNAs. While the safety and off-target effects of this dual double-strand break approach remain uncertain, Guggenheim identified a potential niche market within ASCVD patients requiring a significant reduction in LDL-C levels. Six analysts have revised their earnings forecasts upwards for the upcoming period, although InvestPro suggests the stock is currently trading near its fair value. Editas Medicine plans to commence a Phase 1/2a clinical trial for EDIT-401 in the fourth quarter of 2026.",
  "summary": null,
  "key_points": [
    "Guggenheim upgraded Editas Medicine stock rating to Buy",
    "EDIT-401 gene editing therapy targets severe hypercholesterolemia",
    "Phase 1/2a clinical trial planned for 2026"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}